Abstract

Polo-like kinase 1 (PLK1) is a serine/threonine kinase that plays critical roles in cell cycling and DNA damage response. Overexpression of PLK1 is associated with the poorer prognosis of cancers, including colorectal cancer (CRC). Although the downstream pathways of the overexpression that lead to oncogenesis have been extensively studied, little is known about the factors that cause the overexpression of PLK1 in CRC. DNA methylation was reported to be affecting the expression of PLK1 in some cancers. The study aims to investigate the contribution of genetic mutation and DNA methylation of the PLK1 gene to the overexpression of PLK1 in CRC. The study involves data mining from Catalogue of Somatic Mutations in Cancer (COSMIC) and UniProtKB, Sanger sequencing on DNA from the cell lines HCT116, SW48, Colo320DM and T84 to analyse the possible mutation of PLK1. Other than that methylation status of the PLK1 promoter in CRC are also analysed by using mass spectrometry (MS) and pyrosequencing. Data from the COSMIC show the low incidences of PLK1 mutation for CRC (3.02%) with 46 mutations identified. One of the mutation p.R337Q (c.1010G > A) is located in the D-box which is an important motif for protein ubiquitination and eventually proteasomal degradation. Hence this mutation may potentially result in stabilisation of the PLK1 protein. Mutations are detected at the upstream silencer region, the promoter region and Exon1 in HCT116 but are not located at the protein binding or functioning site. Similarly, the same mutation at promoter region is detected in SW48. Differential trends of changes in methylation status of PLK1 in the IR treated CRC cell lines detected by MS reveal the possible association between the methylation and the radiosensitivity. Furthermore, pyrosequencing shows that PLK1 methylation status in tumour tissues with high expression of PLK1 is not significantly different from those with no PLK1 expression. In conclusion, mutation of PLK1 gene is infrequent in CRC and the expression of PLK1 is unlikely to be dependent on DNA methylation in the promoter region of PLK1 in the CRC.

Highlights

  • Polo-like kinase is a serine/threonine kinase that promotes mitotic entry during cell division [1]

  • The study involves data mining from Catalogue of Somatic Mutations in Cancer (COSMIC) and UniProtKB, Sanger sequencing on DNA from the cell lines HCT116, SW48, Colo320DM and T84 to analyse the possible mutation of Polo-like kinase 1 (PLK1)

  • Data deposited to COSMIC shows 0.39% mutation rate in PLK1 in a sample size of 38,036 specimens

Read more

Summary

Introduction

Polo-like kinase is a serine/threonine kinase that promotes mitotic entry during cell division [1]. The overexpression of PLK1 is associated with poorer prognosis in many cancers [2], including colorectal cancer (CRC) [3]. The expression of PLK1 is variable in both normal and tumour tissues. This had led to the massive development of PLK1 inhibitors, trying to target the PLK1 to improve the treatment outcomes [4] [5] [6] [7]. Since PLK1 is interacting within the complicated cell cycle network and DNA damage response that the activity or expression can be regulated by various factors, the upstream protein or factors may have contributed to the complexity of the development of PLK1 as a target for antitumour. Understanding the mechanisms that result in overexpression PLK1 is critical

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call